Fluvoxamine

Generic Name: Fluvoxamine

Brand Names: Luvox

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₁F_₃N_₂O_₂

CAS Number: 54739-18-3

Unique Ingredient Identifier: O4L1XPO44W

Background: Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder.
...

Indication: Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) . Has also been used in the management of bulimia nervosa .

Associated Conditions: Bulimia Nervosa, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Tasimelteon
Drug: Fluvoxamine

First Posted Date: 2012-02-28

Last Posted Date: 2014-02-17

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT01540500

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, Springfield, Missouri, United States

Impact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel

Phase 1

Completed

Conditions: Drug Interactions Between Clopidogrel and Serotonin Reuptake Inhibitors

Interventions: Drug: citalopharm
Drug: fluvoxamine

First Posted Date: 2011-07-19

Last Posted Date: 2013-01-29

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 15

Registration Number: NCT01396720

Impact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel

Phase 1

Completed

Conditions: Drug Interaction of Clopidogrel

Interventions: Drug: placebo
Drug: omeprazole
Drug: fluvoxamine

First Posted Date: 2011-01-04

Last Posted Date: 2015-08-19

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 15

Registration Number: NCT01269333

Locations: 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel

Fluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?

Phase 3

Completed

Conditions: Autism

Interventions: Drug: Placebo
Drug: fluvoxamine
Drug: sertraline

First Posted Date: 2008-04-09

Last Posted Date: 2008-04-09

Lead Sponsor: The Hospital for Sick Children

Target Recruit Count: 108

Registration Number: NCT00655174

Locations: 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada

Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function

Not Applicable

Conditions: Schizophrenia

Interventions: Drug: Fluvoxamine

First Posted Date: 2008-03-27

Last Posted Date: 2009-02-19

Lead Sponsor: Sha'ar Menashe Mental Health Center

Target Recruit Count: 15

Registration Number: NCT00645580

Locations: 🇮🇱
Sha'ar Menashe Mental Health Center, Mobile Post Hefer, Israel

AV650 Drug-Drug Interaction Study

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-04-05

Last Posted Date: 2007-09-17

Lead Sponsor: Avigen

Target Recruit Count: 30

Registration Number: NCT00456560

Locations: 🇺🇸
Covance Global Clinical Pharmacology Inc., San Diego, California, United States

Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents

Phase 4

Terminated

Conditions: Obsessive Compulsive Disorder

Interventions: Drug: Placebo
Drug: Fluvoxamine maleate

First Posted Date: 2006-07-17

Last Posted Date: 2010-03-04

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT00352768

Locations: 🇯🇵
S114.3.118 Hyogo Children's Hospital, Hyogo prefecture, Japan
🇯🇵
S114.3.118 Hiroshima-city Funairi Hospital, Hiroshima prefecture, Japan
🇯🇵
S114.3.118 Goryokai Hospital, Hokkaido prefecture, Japan

and more 8 locations

Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Fluvoxamine maleate

First Posted Date: 2006-07-17

Last Posted Date: 2010-03-04

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 90

Registration Number: NCT00353028

Locations: 🇯🇵
S114.3.117 Aichi Children's Health and Medical Cen, Nagoya prefecture, Japan
🇯🇵
S114.3.117 Kohnodai Hospital, National Center of N, Chiba prefecture, Japan
🇯🇵
S114.3.117 Hiroshima-city Funairi Hospital, Hiroshima prefecture, Japan

and more 22 locations

Treatment of Youth With ADHD and Anxiety

Not Applicable

Completed

Conditions: Attention Deficit Hyperactivity Disorder
Anxiety, Separation
Social Phobia
Generalized Anxiety Disorder

First Posted Date: 2001-03-16

Last Posted Date: 2009-06-24

Lead Sponsor: National Institute of Mental Health (NIMH)

Target Recruit Count: 120

Registration Number: NCT00012584

Locations: 🇺🇸
UCLA Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
New York University Child Study Center, New York, New York, United States

and more 2 locations

Treatment for Anxiety in Children

Phase 3

Completed

Conditions: Obsessive-Compulsive Disorder
Anxiety Disorders
Generalized Anxiety Disorder
Social Phobia
Separation Anxiety

First Posted Date: 1999-11-03

Last Posted Date: 2007-06-14

Lead Sponsor: National Institute of Mental Health (NIMH)

Registration Number: NCT00000389

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy